GE HEALTHCARE MEDICAL IMAGING AGENTS CERTIFIED HALAL
DEC 19, 2019 @ 9.30AM
Two GE Healthcare contrast agents have been certified halal, increasing radiologists’ choice for their patients in Malaysia. Omnipaque and Visipaque, which together constitute more than one third of the global contrast media market, were certified globally.
The certification is an example of GE Healthcare’s commitment to continually improve healthcare access in the markets that it operates in. This certification of both pharmaceutical drug products requires audits of their manufacturing sites and evaluation of the ingredients to ensure that the products meet the required standards.
Contrast agents are pharmaceutical drug products used in around half of X-ray and CT procedures globally to improve the visibility of specific organs, blood vessels or tissues, helping radiologists distinguish between normal and abnormal conditions.
GE Healthcare is the global market leader in X-Ray and CT contrast agents which are produced and shipped from facilities in Cork, Ireland, and Shanghai, China, to over 100 countries around the world.
“Malaysia is an important market for GE Healthcare in Southeast Asia and we are supportive of the Malaysian government’s efforts to drive high healthcare standards for its people.
Omnipaque and Visipaque have been used for decades around the world to support effective diagnosis. This certification will ensure that those who require or have a preference for halal-certified pharmaceuticals will have access to the healthcare innovations and diagnostic services they need,” said Dr Ibrahim Hashmi the General Manager of GE Healthcare Pharmaceutical Diagnostics, ASEAN.
As part of the halal certification requirement, the certification will be re-evaluated annually. This however, will not impact the price of the products.
The culture of colourism: The obsession with lighter skin tones driving opportunities in the skin lighteners market
Arson, animal cruelty and lack of remorse - traits of personality disorders to look out for in a person
University Malaya Medical Centre inks deal to make Uniportal VATS more affordable for lung cancer patients
Digital Health Malaysia takes health transformation to new heights with fourth telemedicine conference
Roche launch Perjeta - Herceptin combination, a post surgery treatment for early breast cancer (eBC)
Keytruda with chemotherapy to be the first line of treatment for patients with advanced lung cancer
33% below 15 exposed to sexual intercourse, at higher risk of developing cervical cancer says oncologist
Breast cancer survivor emphasizes on monthly self-examination, says no alternative therapy, magic pill for cure